Cargando…

Biologic treatment of Japanese patients with inflammatory bowel disease

BACKGROUND: There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD. METHODS: An online survey was conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlich, Jörg, Matsuoka, Katsuyoshi, Sruamsiri, Rosarin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211510/
https://www.ncbi.nlm.nih.gov/pubmed/30384833
http://dx.doi.org/10.1186/s12876-018-0892-x
_version_ 1783367349712191488
author Mahlich, Jörg
Matsuoka, Katsuyoshi
Sruamsiri, Rosarin
author_facet Mahlich, Jörg
Matsuoka, Katsuyoshi
Sruamsiri, Rosarin
author_sort Mahlich, Jörg
collection PubMed
description BACKGROUND: There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD. METHODS: An online survey was conducted among Japanese patients with IBD (n = 1035). Socioeconomic as well as treatment related information was collected. Logistic regression was applied to analyze the determinants of biologic treatment. RESULTS: Younger age (≤ 40 years vs. > 65 years; OR:0.24), time since diagnosis (< 2 years vs. < 15 years; OR: 4.16), surgical history (OR:1.98) and visiting university hospitals (university hospitals vs. clinics; OR: 0.47) were associated with biologic treatment for Japanese IBD patients. CONCLUSIONS: Currently, biologics have been used in younger IBD patients which may give rise to the presence of an age bias in biologic treatment. Further studies are required to confirm these results and to define appropriate IBD patients who should be treated with biologic agent.
format Online
Article
Text
id pubmed-6211510
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62115102018-11-08 Biologic treatment of Japanese patients with inflammatory bowel disease Mahlich, Jörg Matsuoka, Katsuyoshi Sruamsiri, Rosarin BMC Gastroenterol Research Article BACKGROUND: There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD. METHODS: An online survey was conducted among Japanese patients with IBD (n = 1035). Socioeconomic as well as treatment related information was collected. Logistic regression was applied to analyze the determinants of biologic treatment. RESULTS: Younger age (≤ 40 years vs. > 65 years; OR:0.24), time since diagnosis (< 2 years vs. < 15 years; OR: 4.16), surgical history (OR:1.98) and visiting university hospitals (university hospitals vs. clinics; OR: 0.47) were associated with biologic treatment for Japanese IBD patients. CONCLUSIONS: Currently, biologics have been used in younger IBD patients which may give rise to the presence of an age bias in biologic treatment. Further studies are required to confirm these results and to define appropriate IBD patients who should be treated with biologic agent. BioMed Central 2018-11-01 /pmc/articles/PMC6211510/ /pubmed/30384833 http://dx.doi.org/10.1186/s12876-018-0892-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mahlich, Jörg
Matsuoka, Katsuyoshi
Sruamsiri, Rosarin
Biologic treatment of Japanese patients with inflammatory bowel disease
title Biologic treatment of Japanese patients with inflammatory bowel disease
title_full Biologic treatment of Japanese patients with inflammatory bowel disease
title_fullStr Biologic treatment of Japanese patients with inflammatory bowel disease
title_full_unstemmed Biologic treatment of Japanese patients with inflammatory bowel disease
title_short Biologic treatment of Japanese patients with inflammatory bowel disease
title_sort biologic treatment of japanese patients with inflammatory bowel disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211510/
https://www.ncbi.nlm.nih.gov/pubmed/30384833
http://dx.doi.org/10.1186/s12876-018-0892-x
work_keys_str_mv AT mahlichjorg biologictreatmentofjapanesepatientswithinflammatoryboweldisease
AT matsuokakatsuyoshi biologictreatmentofjapanesepatientswithinflammatoryboweldisease
AT sruamsirirosarin biologictreatmentofjapanesepatientswithinflammatoryboweldisease